Summary
The FDA's compounding advisory committee is set to review seven peptides on July 23 and 24 for potential approval, which could open up a multibillion-dollar market for telehealth companies like Hims & Hers. This decision follows the success of compounded GLP-1 drugs and could lead to a new wave of wellness peptide offerings, despite concerns about long-term safety data for these compounds.